Trial Profile
A phase II open-label multicentre study of the efficacy of ZD1839 (Iressa (TM)) in combination with irradiation followed by chemotherapy in patients with inoperable stage III non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
- 18 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 24 Mar 2006 New trial record.